---
title: Effect of Exenatide on disease progression in early Parkinson’s disease.
euct_id: 2024-520069-30-00
eudra_ct_number: 2019-000732-26
phase: Phase 4
status: Recruiting
sponsor: Region Stockholm – SLSO
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-520069-30-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-520069-30-00"
ctis_last_updated: "2024-12-28T02:00:19.174089544"
source: EU Clinical Trials Information System (CTIS)
---
# Effect of Exenatide on disease progression in early Parkinson’s disease.

**EU CT Number:** [2024-520069-30-00](https://euclinicaltrials.eu/ctis-public/view/2024-520069-30-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Region Stockholm – SLSO
- **Start Date:** 2019-09-02
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson's disease
- **Interventions:** Bydureon 2 mg powder and solvent for prolonged-release suspension for injection, Powder and solvent for prolongedrelease suspension for injection in pre-filled pen

## Member States

Trial is authorized in 1 member state: Sweden.

## Sites (1)

- Region Stockholm – SLSO, Stockholm, Sweden

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-520069-30-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-520069-30-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-520069-30-00*